USAQOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
QHSLab, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.32+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $7.38M
- P/E (TTM)
- –
- Dividend yield
- –
QHSLab, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Integrated Service Program [Member] | $1.12M | $643.21K | $270.02K | 41.7% | +74.3% |
| Allergy Diagnostic Kit Sales [Member] | $823.11K | $832.99K | $666.60K | 30.6% | -1.2% |
| Immunotherapy Treatment Sales [Member] | $487.76K | $409.32K | $363.18K | 18.1% | +19.2% |
| Clinical Study Revenue [Member] | $133.65K | $133.65K | – | 5.0% | 0.0% |
| Subscription Revenue [Member] | $43.73K | $54.52K | $72.20K | 1.6% | -19.8% |
| Shipping and Handling [Member] | $41.67K | $35.89K | $32.34K | 1.5% | +16.1% |
| Training And Other Revenue [Member] | $40.69K | $22.34K | $4.65K | 1.5% | +82.1% |
By region
From the segment and revenue-disaggregation notes of QHSLab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.